T Cell Immunotherapy Development Services
T-cell immunotherapy is an innovative approach in the field of cancer treatment that utilizes the power of the body's immune system to combat cancer cells. It involves modifying or manipulating a specific type of immune cell called T cells to enhance their anti-tumor ability. As a leading preclinical research service provider in leukemia cell therapy, Alfa Cytology provides a series of T-cell immunotherapy development services.
Introduction to T Cell Immunotherapy
T cells are an important component of the human immune system, playing a crucial role in identifying and eliminating abnormal cells, including cancer cells. However, cancer cells can evade the immune system surveillance or create an immunosuppressive environment sometimes, leading to uncontrolled growth and spread.
Fig. 1. The role of T cells in cancer immunotherapy. (Ahmed H.; et al., 2022)
T cell immunotherapy can overcome the challenges above by modifying or activating T cells to recognize and destroy cancer cells more effectively. It has successfully treated various types of hematological malignancies, such as acute lymphocytic leukemia (ALL) and certain types of lymphoma.
| Targets - Company | Therapy | Disease |
|---|---|---|
| CD70 - Adaptimmune | TCR T cell therapy | Acute myeloid leukemia (AML) |
| CD19 - Allogene | CAR T cell therapy | Chronic lymphocytic leukemia (CLL) |
Cellular immunotherapy is a therapy method that utilizes the cells of the human immune system to eliminate cancer. Some of these methods involve directly isolating immune cells and simply increasing their numbers, while others involve genetic engineering of immune cells to enhance their anti-cancer ability. Alfa Cytology provides multiple services for T-cell immunotherapy development, promoting the transformation of T-cell therapies from laboratory to clinical practice.
- Expressing chimeric antigen receptors.
- CAR consists of an antigen recognition domain and a signal domain, which activates T cell function.
- Identifying and targeting specific antigens expressed on cancer cells.
- Treating certain blood cancers, such as leukemia and lymphoma.
- Expressing T cell receptors (TCRs) with enhanced specificity for target antigens.
- TCR is a naturally occurring receptor on T cells that can recognize specific antigenic peptides presented by the major histocompatibility complex (MHC).
- Treating solid tumors and other malignant tumors.
- Having a unique TCR that differs from alpha beta T cells involved in CAR and TCR engineering T cell therapies.
- Identify multiple antigens, including stress-induced molecules on cancer cells.
- Having innate and adaptive immune characteristics.
Why Choose Us?
Professional
Technical
Platform
Extensive
Development
Experience
Highly
Sophisticated
Scientists
Preferential
Prices
T cell immunotherapy has great potential as a revolutionary approach to combat cancer and change the pattern of cancer therapy by utilizing the power of T cells and their inherent ability to recognize and eliminate cancer cells. Alfa Cytology is committed to research and technology related to T-cell immunotherapy, paving the way for more effective and personalized therapy strategies. Contact us immediately to discuss your project or inquire about our T-cell immunotherapy development services. Our team is eager to collaborate and help you turn therapeutic innovation into reality.
Reference
- Ahmed H., et al. Role of T cells in cancer immunotherapy: Opportunities and challenges. Cancer Pathog Ther. 2022;1(2):116-126. Published 2022 Dec 20. doi:10.1016/j.cpt.2022.12.002.